Justus-Liebig-Universitaet Giessen
- Address
- lock Available on a paid plan
Eye Diseases Research
The clinical trial activity at Justus-Liebig-Universitaet Giessen focuses on eye diseases, with studies centered on conditions that can seriously affect vision and daily life. The main research interests include geographic atrophy and macular edema due to central retinal vein occlusion, reflecting a strong commitment to improving care in retinal disease.
- Evaluation of new approaches for geographic atrophy linked to age-related macular degeneration
- Assessment of treatments for macular edema caused by central retinal vein occlusion
- Research aimed at testing whether vision-related disease progression can be slowed or better controlled
- Clinical work focused on improving treatment effectiveness and long-term patient outcomes in retinal disorders
These trials bring together a large investigator team and a clear ophthalmology focus, supporting research that explores both novel therapy options and ways to optimize existing treatment strategies.
Retinal Disease Studies
At the Klinik und Poliklinik für Augenheilkunde, current research is directed toward retinal conditions that can lead to progressive visual impairment. The studies are designed to examine whether new treatment strategies can better address geographic atrophy and improve management of macular edema due to central retinal vein occlusion.
- Investigation of therapies for retinal degeneration in geographic atrophy
- Testing treatment options for swelling and fluid-related vision problems in central retinal vein occlusion
- Work focused on reducing disease burden and preserving sight over time
- Clinical evaluation of strategies intended to improve the durability of eye care treatments
The site’s research profile highlights a practical interest in both innovative treatment development and the refinement of established ophthalmic care for patients with chronic retinal disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 25 therapeutic areas and 15 of 483 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 469 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 93 by active trials.
- 1AstraZeneca AB7active
lock +92 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC12trials
lock +50 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Justus-Liebig-Universitaet Giessen
lock Showing 1 of 278 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 483 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 34 | Unknown | 2019-08-02 | 2026-03-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.